Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. Fundamental Analysis
Spyre Therapeutics, Inc. (SYRE) shows weak financial fundamentals with a PE ratio of -108.34, profit margin of -1.72%, and ROE of -29.44%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -128.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SYRE's fundamental strength across five key dimensions:
Efficiency Score
WeakSYRE struggles to generate sufficient returns from assets.
Valuation Score
ModerateSYRE shows balanced valuation metrics.
Growth Score
ModerateSYRE shows steady but slowing expansion.
Financial Health Score
ExcellentSYRE maintains a strong and stable balance sheet.
Profitability Score
WeakSYRE struggles to sustain strong margins.
Key Financial Metrics
Is SYRE Expensive or Cheap?
P/E Ratio
SYRE trades at -108.34 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SYRE's PEG of 2.07 indicates potential overvaluation.
Price to Book
The market values Spyre Therapeutics, Inc. at 23.51 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -16.85 times EBITDA. This is generally considered low.
How Well Does SYRE Make Money?
Net Profit Margin
For every $100 in sales, Spyre Therapeutics, Inc. keeps $-1.72 as profit after all expenses.
Operating Margin
Core operations generate -2.32 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-29.44 in profit for every $100 of shareholder equity.
ROA
Spyre Therapeutics, Inc. generates $-19.95 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Spyre Therapeutics, Inc. generates limited operating cash flow of $-29.54M, signaling weaker underlying cash strength.
Free Cash Flow
Spyre Therapeutics, Inc. generates weak or negative free cash flow of $-29.54M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.49 in free cash annually.
FCF Yield
SYRE converts -5.92% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-108.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.07
vs 25 benchmark
P/B Ratio
Price to book value ratio
23.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
32.43
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
13.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.29
vs 25 benchmark
ROA
Return on assets percentage
-0.20
vs 25 benchmark
ROCE
Return on capital employed
-0.29
vs 25 benchmark
How SYRE Stacks Against Its Sector Peers
| Metric | SYRE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -108.34 | 28.25 | Better (Cheaper) |
| ROE | -29.44% | 816.00% | Weak |
| Net Margin | -171.51% | -22923.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.31 | Strong (Low Leverage) |
| Current Ratio | 13.25 | 2952.51 | Strong Liquidity |
| ROA | -19.95% | -14992.00% (disorted) | Weak |
SYRE outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Spyre Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
98.82%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
98.62%
Industry Style: Defensive, Growth, Innovation
High Growth